References
[1] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer Statistics, 2021, CA Cancer J Clin 71 (2021) 7-33. 10.3322/caac.21654.
[2] S.E. Waggoner, Cervical cancer, Lancet 361 (2003) 2217-2225. 10.1016/S0140-6736(03)13778-6.
[3] L.T. Gien, A. Covens, Lymph node assessment in cervical cancer: prognostic and therapeutic implications, J Surg Oncol 99 (2009) 242-247. 10.1002/jso.21199.
[4] D. Cibula, W.G. McCluggage, Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions, Gynecol Oncol 152 (2019) 202-207. 10.1016/j.ygyno.2018.10.007.
[5] S. Wu, J. Zheng, Y. Li, H. Yu, S. Shi, W. Xie, H. Liu, Y. Su, J. Huang, T. Lin, A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer, Clin Cancer Res 23 (2017) 6904-6911. 10.1158/1078-0432.CCR-17-1510.
[6] K. Li, H. Sun, Q. Guo, Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: A multiparametric PET-CT study, Eur J Radiol 113 (2019) 153-157. 10.1016/j.ejrad.2019.02.013.
[7] Q. Guo, J. Zhu, Y. Wu, H. Wen, L. Xia, M. Yu, S. Wang, X. Ju, X. Wu, Comparison of different lymph node staging systems in patients with node-positive cervical squamous cell carcinoma following radical surgery, J Cancer 11 (2020) 7339-7347. 10.7150/jca.48085.
[8] J.S. Lea, K.Y. Lin, Cervical cancer, Obstet Gynecol Clin North Am 39 (2012) 233-253. 10.1016/j.ogc.2012.02.008.
[9] M. Undurraga, P. Loubeyre, J.B. Dubuisson, D. Schneider, P. Petignat, Early-stage cervical cancer: is surgery better than radiotherapy?, Expert Rev Anticancer Ther 10 (2010) 451-460. 10.1586/era.09.192.
[10] M.L. Newman, M. Brennan, S. Passik, Lymphedema complicated by pain and psychological distress: a case with complex treatment needs, J Pain Symptom Manage 12 (1996) 376-379. 10.1016/s0885-3924(96)00187-x.
[11] H. Hareyama, K. Hada, K. Goto, S. Watanabe, M. Hakoyama, K. Oku, Y. Hayakashi, E. Hirayama, K. Okuyama, Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study, Int J Gynecol Cancer 25 (2015) 751-757. 10.1097/IGC.0000000000000405.
[12] W.H. Fridman, J. Galon, F. Pages, E. Tartour, C. Sautes-Fridman, G. Kroemer, Prognostic and predictive impact of intra- and peritumoral immune infiltrates, Cancer Res 71 (2011) 5601-5605. 10.1158/0008-5472.CAN-11-1316.
[13] T.L. Whiteside, Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects, Adv Exp Med Biol 451 (1998) 167-171.
[14] S. Karaman, M. Detmar, Mechanisms of lymphatic metastasis, J Clin Invest 124 (2014) 922-928. 10.1172/JCI71606.
[15] C. Balsat, S. Blacher, M. Herfs, M. Van de Velde, N. Signolle, P. Sauthier, C. Pottier, S. Gofflot, M. De Cuypere, P. Delvenne, F. Goffin, A. Noel, F. Kridelka, A specific immune and lymphatic profile characterizes the pre-metastatic state of the sentinel lymph node in patients with early cervical cancer, Oncoimmunology 6 (2017) e1265718. 10.1080/2162402X.2016.1265718.
[16] K. Kawada, M.M. Taketo, Significance and mechanism of lymph node metastasis in cancer progression, Cancer Res 71 (2011) 1214-1218. 10.1158/0008-5472.CAN-10-3277.
[17] F. Pouliot, M. Johnson, L. Wu, Non-invasive molecular imaging of prostate cancer lymph node metastasis, Trends Mol Med 15 (2009) 254-262. 10.1016/j.molmed.2009.04.004.
[18] Y.K. Huang, M. Wang, Y. Sun, N. Di Costanzo, C. Mitchell, A. Achuthan, J.A. Hamilton, R.A. Busuttil, A. Boussioutas, Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry, Nat Commun 10 (2019) 3928. 10.1038/s41467-019-11788-4.
[19] W.C.C. Tan, S.N. Nerurkar, H.Y. Cai, H.H.M. Ng, D. Wu, Y.T.F. Wee, J.C.T. Lim, J. Yeong, T.K.H. Lim, Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy, Cancer Commun (Lond) 40 (2020) 135-153. 10.1002/cac2.12023.
[20] I.P. Nearchou, B.M. Gwyther, E.C.T. Georgiakakis, C.G. Gavriel, K. Lillard, Y. Kajiwara, H. Ueno, D.J. Harrison, P.D. Caie, Spatial immune profiling of the colorectal tumor microenvironment predicts good outcome in stage II patients, NPJ Digit Med 3 (2020) 71. 10.1038/s41746-020-0275-x.
[21] J. Zou, W. Qin, L. Yang, L. Wang, Y. Wang, J. Shen, W. Xiong, S. Yu, S. Song, J.A. Ajani, S.Y. Lin, G.B. Mills, X. Yuan, J. Chen, G. Peng, Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer, Am J Cancer Res 10 (2020) 3947-3972.
[22] N. Lykkegaard Andersen, A. Brugmann, G. Lelkaitis, S. Nielsen, M. Friis Lippert, M. Vyberg, Virtual Double Staining: A Digital Approach to Immunohistochemical Quantification of Estrogen Receptor Protein in Breast Carcinoma Specimens, Appl Immunohistochem Mol Morphol 26 (2018) 620-626. 10.1097/PAI.0000000000000502.
[23] M.I. Toki, C.R. Merritt, P.F. Wong, J.W. Smithy, H.M. Kluger, K.N. Syrigos, G.T. Ong, S.E. Warren, J.M. Beechem, D.L. Rimm, High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling, Clin Cancer Res 25 (2019) 5503-5512. 10.1158/1078-0432.CCR-19-0104.
[24] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646-674. 10.1016/j.cell.2011.02.013.
[25] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57-70. 10.1016/s0092-8674(00)81683-9.
[26] P. Hainaut, A. Plymoth, Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy, Curr Opin Oncol 25 (2013) 50-51. 10.1097/CCO.0b013e32835b651e.
[27] B. Glinsmann-Gibson, L. Wisner, M. Stanton, B. Larsen, L. Rimsza, A. Maguire, Recommendations for Tissue Microarray Construction and Quality Assurance, Appl Immunohistochem Mol Morphol 28 (2020) 325-330. 10.1097/PAI.0000000000000739.
[28] Z. Wang, Y. Liu, L. Lu, L. Yang, S. Yin, Y. Wang, Z. Qi, J. Meng, R. Zang, G. Yang, Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis, Oncotarget 6 (2015) 6670-6683. 10.18632/oncotarget.3118.
[29] D. Brandt, C.M. Hedrich, TCRalphabeta(+)CD3(+)CD4(-)CD8(-) (double negative) T cells in autoimmunity, Autoimmun Rev 17 (2018) 422-430. 10.1016/j.autrev.2018.02.001.
[30] A.M. van der Leun, D.S. Thommen, T.N. Schumacher, CD8(+) T cell states in human cancer: insights from single-cell analysis, Nat Rev Cancer 20 (2020) 218-232. 10.1038/s41568-019-0235-4.
[31] T. Michel, A. Poli, A. Cuapio, B. Briquemont, G. Iserentant, M. Ollert, J. Zimmer, Human CD56bright NK Cells: An Update, J Immunol 196 (2016) 2923-2931. 10.4049/jimmunol.1502570.
[32] R.P. da Silva, S. Gordon, Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein, Biochem J 338 ( Pt 3) (1999) 687-694.
[33] A.H. Sharpe, K.E. Pauken, The diverse functions of the PD1 inhibitory pathway, Nat Rev Immunol 18 (2018) 153-167. 10.1038/nri.2017.108.
[34] Y.Q. Huang, C.H. Liang, L. He, J. Tian, C.S. Liang, X. Chen, Z.L. Ma, Z.Y. Liu, Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer, J Clin Oncol 34 (2016) 2157-2164. 10.1200/JCO.2015.65.9128.
[35] J.X. Zhang, W. Song, Z.H. Chen, J.H. Wei, Y.J. Liao, J. Lei, M. Hu, G.Z. Chen, B. Liao, J. Lu, H.W. Zhao, W. Chen, Y.L. He, H.Y. Wang, D. Xie, J.H. Luo, Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis, Lancet Oncol 14 (2013) 1295-1306. 10.1016/S1470-2045(13)70491-1.
[36] T. Shiraishi, E. Shinto, I.P. Nearchou, H. Tsuda, Y. Kajiwara, T. Einama, P.D. Caie, Y. Kishi, H. Ueno, Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays, Virchows Arch 477 (2020) 409-420. 10.1007/s00428-020-02775-y.
[37] T.F. Cloughesy, A.Y. Mochizuki, J.R. Orpilla, W. Hugo, A.H. Lee, T.B. Davidson, A.C. Wang, B.M. Ellingson, J.A. Rytlewski, C.M. Sanders, E.S. Kawaguchi, L. Du, G. Li, W.H. Yong, S.C. Gaffey, A.L. Cohen, I.K. Mellinghoff, E.Q. Lee, D.A. Reardon, B.J. O’Brien, N.A. Butowski, P.L. Nghiemphu, J.L. Clarke, I.C. Arrillaga-Romany, H. Colman, T.J. Kaley, J.F. de Groot, L.M. Liau, P.Y. Wen, R.M. Prins, Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma, Nat Med 25 (2019) 477-486. 10.1038/s41591-018-0337-7.
[38] N.A. Giraldo, P. Nguyen, E.L. Engle, G.J. Kaunitz, T.R. Cottrell, S. Berry, B. Green, A. Soni, J.D. Cuda, J.E. Stein, J.C. Sunshine, F. Succaria, H. Xu, A. Ogurtsova, L. Danilova, C.D. Church, N.J. Miller, S. Fling, L. Lundgren, N. Ramchurren, J.H. Yearley, E.J. Lipson, M. Cheever, R.A. Anders, P.T. Nghiem, S.L. Topalian, J.M. Taube, Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab, J Immunother Cancer 6 (2018) 99. 10.1186/s40425-018-0404-0.
[39] V.H. Koelzer, K. Sirinukunwattana, J. Rittscher, K.D. Mertz, Precision immunoprofiling by image analysis and artificial intelligence, Virchows Arch 474 (2019) 511-522. 10.1007/s00428-018-2485-z.
[40] O. Luhrs, L. Ekdahl, B. Geppert, C. Lonnerfors, J. Persson, Resection of the upper paracervical lymphovascular tissue should be an integral part of a pelvic sentinel lymph node algorithm in early stage cervical cancer, Gynecol Oncol 163 (2021) 289-293. 10.1016/j.ygyno.2021.08.031.
[41] H. Wu, S. Song, A. Yan, X. Guo, L. Chang, L. Xu, L. Hu, M. Kuang, B. Liu, D. He, R. Zhao, L. Wang, X. Wu, J. Gu, Y. Ruan, RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1, Cancer Lett 469 (2020) 287-300. 10.1016/j.canlet.2019.11.002.
[42] C. Shang, W. Wang, Y. Liao, Y. Chen, T. Liu, Q. Du, J. Huang, Y. Liang, J. Liu, Y. Zhao, L. Guo, Z. Hu, S. Yao, LNMICC Promotes Nodal Metastasis of Cervical Cancer by Reprogramming Fatty Acid Metabolism, Cancer Res 78 (2018) 877-890. 10.1158/0008-5472.CAN-17-2356.
[43] A. Carbone, A. Gloghini, G. Pruneri, R. Dolcetti, Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment, Cancer Med 8 (2019) 3012-3016. 10.1002/cam4.2168.